Brown Advisory Inc. Has $26.22 Million Holdings in Sanofi $SNY

Brown Advisory Inc. lifted its stake in shares of Sanofi (NASDAQ:SNY) by 6.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 541,121 shares of the company’s stock after buying an additional 30,904 shares during the period. Brown Advisory Inc.’s holdings in Sanofi were worth $26,223,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of SNY. Brighton Jones LLC increased its holdings in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares in the last quarter. AQR Capital Management LLC increased its holdings in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC increased its holdings in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in Sanofi by 36.1% in the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after purchasing an additional 875 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY opened at $43.80 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $106.19 billion, a P/E ratio of 12.23, a price-to-earnings-growth ratio of 1.09 and a beta of 0.34. The firm’s fifty day simple moving average is $45.06 and its two-hundred day simple moving average is $46.48. Sanofi has a 12 month low of $42.28 and a 12 month high of $52.68.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were given a dividend of $2.4225 per share. This represents a yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s payout ratio is currently 49.16%.

Analysts Set New Price Targets

A number of research firms recently weighed in on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Finally, Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.